Baylor study plays up breast implant risk
This article was originally published in Clinica
Animal studies have shown that low molecular weight silicones injected subcutaneously accumulate in vital organs and persist even after a year.
You may also be interested in...
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.